Company Overview and News

 
Toyota to recall 2.4 million hybrid cars globally over faulty program

2018-10-05 japantimes.co.jp
Toyota Motor Corp. said Friday it will recall 2.43 million hybrid cars at home and abroad due to a fault in the hybrid system program.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
UPDATE 2-Japan car makers welcome N.America trade deal, but U.S. export curbs a risk

2018-10-02 reuters
TOKYO (Reuters) - Toyota, Nissan and Mazda welcomed on Tuesday the revised North America trade deal that left Japanese automakers unscathed but they may face a bumpy ride when Washington and Tokyo hold new talks on over $40 billion of annual U.S. auto imports from Japan.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
Mazda picks up the pace in electric vehicles

2018-10-02 theage.com.au
Mazda Motor Corp laid out plans to revamp its product line-up, saying that all its vehicles will come with electric power by 2030. Five per cent of the cars would be fully battery-powered by that year, and 95 per cent would combine an electric motor with an internal-combustion engine, the Japan-based company said on Tuesday.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
Mazda picks up the pace in electric vehicles

2018-10-02 watoday.com.au
Mazda Motor Corp laid out plans to revamp its product line-up, saying that all its vehicles will come with electric power by 2030. Five per cent of the cars would be fully battery-powered by that year, and 95 per cent would combine an electric motor with an internal-combustion engine, the Japan-based company said on Tuesday.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
Mazda picks up the pace in electric vehicles

2018-10-02 smh.com.au
Mazda Motor Corp laid out plans to revamp its product line-up, saying that all its vehicles will come with electric power by 2030. Five per cent of the cars would be fully battery-powered by that year, and 95 per cent would combine an electric motor with an internal-combustion engine, the Japan-based company said on Tuesday.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
Mazda CEO welcomes U.S., Canada agreement on trade pact

2018-10-02 theedgemarkets
TOKYO (Oct 2): Japanese automaker Mazda Motor Corp on Tuesday welcomed a new trade deal between the United States, Mexico and Canada, and said it would work to meet new rules on components used in Mazda vehicles made in Mexico.
7261 MZDAY MZDAF

 
UPDATE 1-Mazda CEO welcomes new U.S., Canada, Mexico trade pact

2018-10-02 reuters
* Mazda now exports cars to U.S. from Japan or its Mexico plant (Adds Mazda CEO’s comments, background on auto trade)
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
Mazda CEO welcomes new U.S., Canada, Mexico trade pact

2018-10-02 reuters
TOKYO (Reuters) - Japanese automaker Mazda Motor Corp (7261.T) welcomed on Tuesday a new trade deal between the United States, Mexico and Canada, and said it would work to meet new rules on components used in Mazda vehicles made in Mexico.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

 
Mazda aims for all of its vehicles to be electric hybrid, EVs by 2030

2018-10-02 moneycontrol
Mazda Motor Corp said on October 2 that all of the vehicles it produces by 2030 will incorporate electrification, while 5 percent of its cars will be all-battery electric vehicles (EVs).
7261 MZDAY MZDAF

 
Mazda CEO welcomes U.S., Canada agreement on trade pact

2018-10-02 reuters
TOKYO (Reuters) - Japanese automaker Mazda Motor Corp (7261.T) on Tuesday welcomed a new trade deal between the United States, Mexico and Canada, and said it would work to meet new rules on components used in Mazda vehicles made in Mexico.
7261 MZDAY MZDAF

 
Mazda aims for all of its vehicles to be electric hybrid, EVs by 2030

2018-10-02 reuters
TOKYO (Reuters) - Mazda Motor Corp said on Tuesday that all of the vehicles it produces by 2030 will incorporate electrification, while 5 percent of its cars will be all-battery electric vehicles (EVs). The Japanese automaker joins a growing number of global automakers who are planning to reduce emissions by producing more gasoline-hybrid vehicles, plug-in hybrids and battery EVs.
7261 MZDAY MZDAF

 
Mazda aims for all of its vehicles to be electric hybrid, EVs by 2030

2018-10-02 channelnewsasia
Mazda Motor Corp said on Tuesday that all of the vehicles it produces by 2030 will incorporate electrification, while 5 percent of its cars will be all-battery electric vehicles (EVs). The Japanese automaker joins a growing number of global automakers who are planning to reduce emissions by producing more gasoline-hybrid vehicles, plug-in hybrids and battery EVs.
7261 MZDAY MZDAF

 
Nikkei retreats after 8-day winning streak; Subaru gains as Japan dodges more tariffs

2018-09-27 reuters
TOKYO, Sept 27 (Reuters) - Japan’s Nikkei snapped an eighth-day winning streak on Thursday, losing ground as profit-taking kicked in, but some automakers rose after the United States indicated it won’t impose further tariffs on Japanese automotive products for now.
7261 MZDAY MZDAF

 
UPDATE 4-Japan dodges U.S. auto tariffs, for now, as Trump and Abe agree on trade talks

2018-09-27 reuters
NEW YORK (Reuters) - U.S. President Donald Trump and Japanese Prime Minister Shinzo Abe agreed on Wednesday to start trade talks in an arrangement that, for now, protects Japanese automakers from further tariffs, seen as a major threat to the export-dependent economy.
7261 MZDAY MZDAF

 
Nikkei edges up in choppy trade; automakers soar after Japan dodges further tariffs

2018-09-27 reuters
TOKYO, Sept 27 (Reuters) - Japan’s Nikkei edged higher in choppy trade on Thursday as automakers rose after the United States indicated it won’t impose further tariffs on Japanese automotive products for now, but gains were limited as investors remained cautious.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...